Argos Therapeutics Enrolls Initial Patients in Pivotal Phase 3 ADAPT Study

  Argos Therapeutics Enrolls Initial Patients in Pivotal Phase 3 ADAPT Study AGS-003, first fully personalized, dendritic-based immunotherapy  being evaluated in combination with targeted therapy for mRCC Visit ADAPTkidneycancer.com & Follow on Twitter @ADAPTkdnycancer DURHAM, N.C. – January 15, 2012 – Argos Therapeutics Inc., a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer and infectious diseases using its Arcelis™ technology platform, announced that the first patients have been enrolled in the ADAPT Phase 3 clinical study for AGS-003, its most advanced product candidate. AGS-003 is an investigational, fully personalized, dendritic-cell based immunotherapy. The ADAPT study is designed to examine the potential for AGS-003 plus standard targeted drug therapy to extend overall survival versus standard therapy alone in newly diagnosed patients with unfavorable risk metastatic renal cell carcinoma (mRCC). The ADAPT study is a randomized, multicenter, open-label clinical trial expected to enroll 450 patients in approximately 120 sites, mostly in North America, under an approved Special Protocol Assessment by the Food and Drug Administration. Secondary endpoints include progression-free survival, safety, overall response and immune response. By the end of first quarter 2013, the company expects to have nearly 70 active sites, pr...
Source: Kidney Cancer Association - Category: Cancer & Oncology Source Type: news